15例甲状腺间变癌临床病理及免疫组化分析

[目的]探讨甲状腺间变癌的临床病理特征和免疫组化结果的意义。[方法]光镜观察和免疫组织化学SP法检测15例甲状腺间变癌。[结果]甲状腺间变癌的病理分型为梭形细胞型、巨细胞型和混合细胞型。15例中免疫组化阳性表达率分别是：Vimentin86．6％(13／15)、CK73．3％(11/15)、CEA60．0％(9／15），CD68 6．6％(1/15)；TG和降钙素均为阴性。2例伴有乳头状癌其中Vimentin和CK均阳性；1例伴破骨样巨细胞CD68阳性。[结论]甲状腺间变癌是上皮源性、恶性度高的肿瘤。熟悉其形态特征．结合免疫组化对诊断甲状腺间变癌具有重要意义。     

Expression of Bcl-2, bax and Bcl-X<Subscript>L</Subscript> in meningioma cells and its clinical significance

Objective To explore the relationship between expression of apoptosis-modulating proteins and histopathological grade and recurrence in meningioma. Methods Immunohistochemistry method (LSAB) was used to detect the expression of Bcl-2, Bax Bnd Bcl-X_L in 80 cases of meningioma including benign group (38 cases), atypical group (26 cases) and malignant group (16 cases). Results Expression of Bcl-2 oncoprotein positive in 88% cases in malignant group was significantly higher than that of benign group (37%,P<0.05). There was no significant difference in the expression positive rate of Bax, Bcl-X_L oncoprotein among benign, atypical and maligant groups (P>0.05), but Bcl-2+Bcl-X_L/Bax was associated statistically with meningioma grade (P<0.01). There was no significant difference in the compare expression of Bcl-2, Bax, Bcl-X_L oncoprotein positive in non-recurrent, initially resected recurrent and recurrent meningiomas (P>0.05). Conclusion Bcl-2, Bax and Bcl-X_L might play important roles in meningiomas and BCL-2+BCL-X_L/Bax is useful parameters for estimation of biological behavior of meningiomas.     

Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival

Despite the use of multimodal therapy, higher-grade glioma is stilluniformly fatal in the adult population. There is a considerable differencebetween the length of survival in each given patient, even within the sametumor type and malignancy grade group, suggesting that there are factorsthat might differentially influence outcome. To identify such factors, 107patients with anaplastic or malignant glioma were retrospectivelyinvestigated. Clinical parameters and paraclinical data on the p53, mdm2,and EGFR genes at the DNA or protein level were evaluated by univariateanalysis and Cox proportional hazards regression modeling. Kaplan-Meiersurvival estimation demonstrated that immunohistochemical positivity formdm2 protein in patients with anaplastic astrocytoma or with glioblastomamultiforme was associated with a shorter survival time (p = 0.02).P53 gene mutations and immunopositivity for the epidermal growth factorreceptor (EGFR) protein were not significantly related to poor prognosis.The Cox proportional hazards model revealed immunohistochemical positivityfor p53, mdm2, or for both of them, the presence of postoperativeirradiation, and the extent of surgical resection of tumor to be variablessignificantly associated with prolonged survival. EGFR overexpression, ageover 60 years, and Karnofsky performance score below 40 points did notsignificantly shorten survival time. In conclusion, the present studyidentified immunohistochemically detected mdm2-protein overexpression as astatistically significant negative prognostic parameter in patients bearinganaplastic or malignant glioma. Association analysis of variables revealed apossible correlation between mdm2 and p53, which is also consistent with thebiological interaction mode of both proteins in vivo.     

Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol,BCNU and procarbazine

Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m² on day 1, BCNU 150 mg/m² on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15. The course was repeated every 4 weeks, but was delayed or decreased by 25% according to hematological toxicity. Response to treatment was evaluated by the criteria of MacDonald et al. (J Clin Oncol 1990; 8: 1277–1280). All GBL-patients were followed until death. One patient with complete response (CR) survived one year, and 2 patients with partial response (PR) survived 1 and 3 years. Ten patients who stabilized (SD) survived 7.5 months, and 13 patients who progressed under chemotherapy had a median survival of 3.5 months. In AA-group 3 patients were alive at the time of the analyses. Six patients: 1 CR and 5 PR survived 6 to 40 + months. Two patients with SD survived 4 and 14 months. Three patients with progressive disease had a mean survived of less than 3 months. The response rate of 55% in AA was significantly higher (p=0.011) than the 12% response rate seen in GBL. We conclude that the regimen tested appears particularly promising in AA. The results in GBL are comparable to those obtained with a single nitrosourea, despite an increased but reversible toxicity.     

Iatrogenic seeding of anaplastic astrocytoma following stereotactic biopsy

We present a case of probable tumor seeding along the needle tract following computer tomography-guided stereotactic biopsy of an anaplastic astrocytoma in a 23 year old male. Six months after the initial biopsy and 3 months following a second stereotactic procedure for cyst aspiration, a second lesion appeared directly along the biopsy trajectory at a distance from the primary tumor. This lesion is presumed to be recurrent tumor and appears to have been spread iatrogenically following the biopsy of the initial tumor and the subsequent cyst aspiration along the same tract.     

A therapeutic trial of radiation therapy with Vincristine,etoposide, and Procarbazine (VVP) in high grade intracranial gliomas

This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.     

视神经鞘脑膜瘤的显微外科治疗(附13例报道)

目的探讨视神经鞘脑膜瘤的显微神经外科手术方法。方法收治13例视神经鞘脑膜瘤，根据肿瘤位置采用3种不同经颅入路：单侧额部入路、经额经眶上缘入路及经额颧经眶上缘入路，利用显微外科技术安全显露眶上裂外侧部、眶上裂中央部切除肿瘤。结果肿瘤全切11例，部分切除2例。术后13例患者的眼球突出均恢复正常，11例其它症状和体征也恢复或改善。术后动眼神经麻痹1例，患侧眼失明2例。结论熟悉显微神经外科解剖学，利用显微外科技术选择合适的经颅入路，可以提高视神经鞘脑膜瘤的全切除率，并使颅眶区的正常结构得到最大程度的保护。     

Spinal Papillary Meningioma: A Case Report and Review of the Literature

Summary  A rare case of a spinal papillary meningioma in a 19-year-old adolescent is described. Six months after radical resection the patient showed dissemination along the cerebrospinal pathway. Papillary meningiomas are rare tumours with a relatively high incidence in childhood. Most papillary meningiomas reported in the literature are considered as aggressive variants of meningioma with often local recurrence, dissemination in the CSF and metastases to remote sites. This case supports that, although the histogenesis remains unexplained, papillary meningiomas deserve recognition on the basis of their high morbidity and mortality.     

Outcome from Complex Neurosurgery: An Evidence Based Approach

Summary ? Background. The aim of this study was to determine outcome, including quality of life, after surgery for petroclival meningioma using a standard skull base approach and to carry out an evidence based appraisal of the relevant literature.  Method. Pre- and post-operative data including adverse events were prospectively recorded in 19 patients (15 females, age range 29–63) undergoing a transpetrous approach for a petroclival meningioma. Patients were assessed using the GOS and SF-36 post operatively.  Findings. 24 operations were done. 6 patients developed a new permanent neurological deficit and 10 experienced a temporary deficit or exacerbation of existing deficits. At 1 year 15 patients had made a good/moderate recovery, 3 were severely disabled and 1 died – in keeping with other studies. By contrast the SF-36 showed that in all 8 categories of the SF-36 between 39–72% of surviving patients were functioning below the accepted norms.  Interpretation. After transpetrous excision of a petroclival meningioma the quality of life for the patient is worse than that indicated in surgeons' reported results. This paper represents an attempt to address the issue of evidence-based medicine and finds that such an approach is not apparent in the medical literature on this pathology. While we argue that methods for measuring outcome should be refined and carers input recognised it does raise certain philosophical considerations. It is the counsel of perfection and if achieved may lead to surgeons operating on fewer patients, more petroclival cases being viewed as inoperable because of the higher morbidity, despite there being an inescapable pathway to surgical intervention.     

A Case of Subcortical Meningioma

Subcortical meningioma, which has been reported as meningioma without dural attachment, a cerebral subcortical lesion, is extremely rare. Very few findings of radiological examination of subcortical meningioma have been described. Pre-operative differentiation of this lesion is generally difficult. We characterize the peritum oural oedema adjacent to the meningioma in this region, and we suggest that radiological findings of peritum oural oedema contribute to differential diagnosis of subcortical meningiomas.